TrialCancer immunology research2026

Induction Serplulimab and Chemotherapy Followed by Chemoradiotherapy for Bulky Unresectable Stage III NSCLC: A Phase II Study (SUCCEED-01).

Chengxin Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.